Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Pei-Rong Ding
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06417476CT.gov Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06048146CT.gov A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis | — | Completed | — | — | — |
NCT03698461CT.gov Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | — | Completed | — | — | — |
NCT03484221CT.gov Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer | — | Unknown | — | — | — |
NCT01609231CT.gov A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | — | Terminated | — | — | — |
NCT00506844CT.gov Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer | — | Unknown | — | — | — |
NCT00506623CT.gov Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer | — | Unknown | — | — | — |
NCT00180960CT.gov Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Pei-Rong Ding | P2 | B · 57 |
| Ertapenem | University of Ulm | P4 | BB |
| Propofol | Uppsala University | P4 | BB |
| Oxaliplatin | Chongqing University Cancer Hospital | P3 | BB |
| Fluorouracilum | Pei-Rong Ding | P3 | BB |
| Sevoflurane | Uppsala University | P4 | BB |
| Capecitabine | Chongqing University Cancer Hospital | P3 | BB |
| Dilaudid | University of Illinois College of Medicine at Peoria | P4 | BB |
| Lidocaine | University of Illinois College of Medicine at Peoria | P4 | BB |
+36 more in the Rectal Neoplasm cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Rectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-rectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →